The trial is being conducted at Memorial Sloan Kettering Cancer Center in New York City. It is evaluating the efficacy of TLX250-targeted radiation in conjunction with the anti-PD-11 immunotherapy Opdivo2 (nivolumab) for aggressive kidney cancer. TLX250 targets a protein commonly found in patients likely to have limited response to cancer immunotherapy, Monrol and Telix said.
Memorial Sloan Kettering has financial interests in Telix, according to the two firms.
Copyright © 2022 AuntMinnieEurope.com